NRAS and melanoma: Crucially, pharmacological co-targeting of NFATc2 and EZH2 exerted significant anti-tumor activity not only against BRAF-mutant melanomas with intrinsic resistance to BRAF inhibitors, but even against NRAS-mutant and BRAF/NRAS wild type melanoma cells.